Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Technology · ·
$104.97
▼ $0.29 (-0.3%)
Market data updated: 09/20 01:38 AM
News analyzed: 09/20/2026
Market Cap
Not available
Day Range
$102.51 - $105.52
52-Week Range
$83.10 - $153.07
Beta
—
Next Earnings
11.11.2026
Support
$86.01
Resistance
$111.15
NICE is a stock from the Technology sector — Software, hardware, chip, and computing-services companies — revenue tied to the pace of innovation and upgrade cycles.
-30.6% (1Y)
🟢 Strong
Strengths: 6/13 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 50
Price is above the 50-day average
Technical
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: -0.24 (3y annualized return -16.1% / max drawdown 68.2%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
NICE (NICE) exhibits a strong overall investor score of 83, driven primarily by robust technical indicators and positive news sentiment, though tempered by significant risk factors. The technical category scores an impressive 85, reflecting a bullish momentum profile with the stock price above both its 50-day and 200-day moving averages, a positive MACD histogram, and an RSI of 55.6, indicating healthy upward momentum. Meanwhile, the news category scores near-perfect at 98, with three positive articles highlighting growth opportunities in healthcare AI and partnerships, outweighing two mildly negative earnings-related critiques. However, the risk category drags the overall score down to 42, exposing severe volatility concerns: a Sharpe ratio of -0.27 over three years (with an 18.5% annualized loss) and a maximum drawdown of 68.2%, signaling extreme price instability. The declining trading volume despite price gains further raises caution about potential weakening interest or liquidity issues.
The stock price is positioned above both the 50-day and 200-day moving averages, with a positive MACD histogram and an RSI of 55.6, indicating strong upward momentum. The %K value of 55.8 remains neutral, suggesting no overbought conditions.
This technical strength signals a favorable short-to-medium-term trend, reinforcing investor confidence in sustained price appreciation.
The news sentiment is overwhelmingly positive, with three articles emphasizing growth in healthcare AI and strategic partnerships, while two articles critique earnings returns. The positive articles far outweigh the negatives.
Positive news can drive investor enthusiasm and justify valuation multiples, while negative earnings commentary may introduce caution regarding profitability.
The stock exhibits extreme volatility, with a Sharpe ratio of -0.27 over three years, a 18.5% annualized loss, and a maximum drawdown of 68.2%. The ATR (3.7% of price) also indicates high volatility.
Such volatility suggests significant price swings and potential for substantial losses, which could deter risk-averse investors or trigger panic selling.
StockIQ conclusion
NICE demonstrates a compelling technical and news-driven narrative, supported by short-term outperformance and AI-related growth opportunities. However, extreme volatility and declining volume introduce significant risks, particularly for investors sensitive to price swings. The stock’s high risk profile, as evidenced by its Sharpe ratio and drawdown, must be carefully weighed against its potential upside. While positive news and technical strength provide a foundation for optimism, the underlying volatility and earnings concerns create a complex risk-reward dynamic.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
67
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
11d ago · $100.95
Evidence: -4.8pp vs. sector average today
What happened after
11d ago · $100.95
Evidence: attention score 79/100
What happened after
11d ago · $105.50
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
11d ago · $105.50
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
12d ago · $105.50
Evidence: -3.2pp vs. sector average today
What happened after
12d ago · $105.50
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
12d ago · $105.50
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
13d ago · $105.50
Evidence: -3.2pp vs. sector average today
What happened after
13d ago · $105.50
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
13d ago · $105.50
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
14d ago · $105.50
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
14d ago · $105.50
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
14d ago · $105.50
Evidence: -3.1pp vs. sector average today
What happened after
15d ago · $105.81
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
15d ago · $105.81
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
16d ago · $109.37
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
16d ago · $109.37
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
17d ago · $106.86
Evidence: -4.3pp vs. sector average today
What happened after
17d ago · $107.01
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
17d ago · $107.01
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
69
$100.43
Now
67
$104.97
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
69
Risk
42
Sentiment
74
Fundamental
No data available
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of NICE Ltd has centered on its expanding AI-driven customer experience (CX) solutions, particularly within healthcare. The company announced AOK PLUS’s adoption of its unified CX AI platform, combining AI agents and member service operations to handle over 5 million annual interactions. Additionally, NICE highlighted Bluecrest Health Intelligence’s use of its CXone platform to modernize contact centers with AI, emphasizing efficiency and resilience. Investor focus also includes NICE’s stock valuation, which remains undervalued despite a 66.9% decline over five years, amid debates over long-term returns.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about NICE Ltd. News trend score: 74. Reason: 9 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
13
🎯 Conviction (vs. Emotion)
50
Psychology
14
Fundamentals
—
Technical
69
Valuation
—
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+24%
Market Narrative
52
Fundamental Reality
50
Narrative Gap
+2
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior here suggests a **herding dynamic** where NICE’s underperformance relative to peers (-1.0% vs -0.5%) may be prompting investors to reassess positioning. While euphoria lingers (19 score) due to extreme sentiment (98/100) and modest momentum, the narrative gap (14 points) hints at a disconnect between optimism and underlying fundamentals. The key question is whether the slight underperformance will deepen or if traders pivot back to the positive narrative. FOMO remains muted by subdued volume (0.73x avg) and neutral RSI (46), while panic selling is negligible given stable volatility (0.91x).
Updated: 09/09/2026, 02:57 PM
What could change this?
👥 What the crowd believes
"Bluecrest Health Intelligence has adopted NICE’s CXone platform to overhaul contact center operations using AI."
"AOK PLUS is now live on NICE Cognigy and CXone, making it one of the first customers to bring AI agents and member service operations together."
"NICE has delivered a decline of about 66.9% over the past 5 years, leaving long-term holders with heavy losses."
"European tech retailer Currys selected NICE CXone to unify customer interactions across every stage of the journey."
🧠 Market Brain events driving this
📈 18D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 76/100
🔴 Weakest match
Morgan Housel — 8/100
🗣️ Why do they disagree?
The model estimates that, based on Samuel Armstrong Nelson’s cycle‑position rules, the stock appears oversold and thus receives a high score of 84, while Charles Mackay’s crowd‑mania test also rates it favorably at 76 because he sees no speculative excess. In contrast, Howard Marks’ market‑cycle and overall risk frameworks place the stock near the middle of the cycle (52) and flag mixed expectations (47), reflecting a more cautious stance. Graham, Fisher, Lynch, Bagehot and the enterprising‑Graham read all default to a neutral 50 because the required balance‑sheet, valuation or growth data are missing, leading to an indeterminate verdict. The most bearish views come from Loeb (32), Veblen (20), Schwager (18), Smith (15), Livermore (13) and Housel (2), each emphasizing risk, trend‑negative signals or volatile price action, which explains their low scores.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 76
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 64
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 53
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 46
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 46
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 34
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 28
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 20
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 12
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 8
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (6 bullish · 2 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 9 positive, 6 neutral, 5 negative out of the last 20 articles.
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
Zacks · 14.9.2026
Benzinga · 14.9.2026
Yahoo · 11.9.2026
Zacks · 11.9.2026
Yahoo · 8.9.2026
Business Wire · 8.9.2026
Yahoo · 7.9.2026
Zacks · 7.9.2026
Yahoo · 31.8.2026
Zacks · 31.8.2026
Yahoo · 29.8.2026
Simply Wall St. · 29.8.2026
Yahoo · 29.8.2026
Simply Wall St. · 29.8.2026
Yahoo · 28.8.2026
Insider Monkey · 28.8.2026
SeekingAlpha · 24.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for NICE Ltd (NICE) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for NICE specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
NICE's technical score is 69/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 50-day average; Price is above the 200-day average; RSI 54.0 — healthy positive momentum.
Based on the real signals StockIQ computed: Calmar: -0.24 (3y annualized return -16.1% / max drawdown 68.2%); MACD histogram is negative — falling momentum; ROC 12 days: -1.5%.
StockIQ has no recorded dividend payment history for NICE.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 1 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Neder Shiri | Grant/Award from Employer | 8.9.2026 | 7,500 | +7,500 | — |
| Simon Zehava | Exercise of Derivative Securities | 13.8.2026 | 554 | -554 | — |
| Simon Zehava | Exercise of Derivative Securities | 13.8.2026 | 554 | +554 | $0.31 |
| Dayan Udi Yehuda | Open Market Sale | 7.8.2026 | 500 | -500 | $100.00 |
| Dayan Udi Yehuda | Exercise of Derivative Securities | 7.8.2026 | 500 | +500 | $0.31 |
| Dayan Udi Yehuda | Exercise of Derivative Securities | 7.8.2026 | 500 | -500 | — |
| Russell Scott Edward | Tax Withholding in Shares | 1.7.2026 | 2,051 | -2,051 | $90.85 |
| Russell Scott Edward | Tax Withholding in Shares | 1.7.2026 | 131,887 | -2,051 | $90.85 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 521 | +521 | $0.28 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 636 | +636 | $0.27 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 696 | +696 | $0.29 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 629 | -629 | — |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 636 | -636 | — |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 521 | -521 | — |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 696 | -696 | — |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 554 | -554 | — |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 629 | +629 | $0.29 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 554 | +554 | $0.31 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 949 | +554 | $0.31 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 1,578 | +629 | $0.29 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 2,274 | +696 | $0.29 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 2,795 | +521 | $0.28 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 3,431 | +636 | $0.27 |
| Dvir Yocheved | Exercise of Derivative Securities | 15.6.2026 | 0 | -636 | — |
| Russell Scott Edward | Grant/Award from Employer | 9.6.2026 | 28,000 | +28,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,245,985 shares short as of 2026-08-31 · vs. 1,844,401 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
56.2% of trading volume this week was short selling, vs. 43.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology